Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers

Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation t(11;14), but questions remain open about its optimal use. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Szita, Virág Réka, Mikala, Gábor, Kozma, András, Fábián, János, Hardi, Apor, Alizadeh, Hussain, Rajnics, Péter, Rejtő, László, Szendrei, Tamás, Váróczy, László, Nagy, Zsolt, Illés, Árpád, Vályi-Nagy, István, Masszi, Tamás, Varga, Gergely
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918485/
https://www.ncbi.nlm.nih.gov/pubmed/35295611
http://dx.doi.org/10.3389/pore.2022.1610276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918485/
https://www.ncbi.nlm.nih.gov/pubmed/35295611
http://dx.doi.org/10.3389/pore.2022.1610276

Ejemplares similares